-------------------------------------------
OMB APPROVAL
-------------------------------------------
OMB Number:
Expires:
Estimated average burden
hours per form...................
-------------------------------------------
UNITED STAES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
SIGA PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
826 917 10 6
- --------------------------------------------------------------------------------
(CUSIP Number)
Adam D. Eilenberg, Esq.
Ehrenreich Eilenberg & Krause LLP
11 East 44th Street, 17th Floor
New York, New York 10017
(212) 986-9700
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 29, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing
of this Statement)
If the filing person has previously filed a statement of Schedule 13G to report
the acquisition which is the subject of the Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with this statement [X].
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filed out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following page(s))
<PAGE>
CUSIP No. 826 917 10 6 13D
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Richard Stone
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [X]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
PF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
USA
- --------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES 548,465
BENEFICIALLY --------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH 0
REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 548,465
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
548,465
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.3%
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Item 1. Security and Issuer.
The title of the class of equity securities to which this statement relates is
the common stock, $.0001 par value per share (the "Common Stock"), of SIGA
Pharmaceuticals, Inc., a Delaware corporation (the "Company"). The principal
executive offices of the Company are located at 420 Lexington Avenue, Suite 620,
New York, NY 10170. This statement is filed pursuant to Rule 13d-2(a) with
respect to securities owned by Richard Stone as of December 29, 1999 and amends
the Schedule 13 D filed on June 3, 1998 (the "Schedule 13D").
Item 2. Identity and Background.
(a) The name of the person filing this Schedule 13D is Richard Stone.
(b) The business address of Mr. Stone is c/o Sunrise Securities Corp., 135
East 57th Street, 11th Floor, New York, New York 10022.
(c) Mr. Stone is a Managing Director of Sunrise Securities Corp., a
registered broker-dealer.
(d) Mr. Stone has not been convicted during the past five years in a
criminal proceeding (excluding traffic violations or similar
misdemeanors).
(e) Mr. Stone has not been, during the last five years, a party to a civil
proceeding of a judicial or administrative body of competent
jurisdiction and has not and is not subject to a judgment, decree or
final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or
finding any violation with respect to such laws.
(f) Mr. Stone is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration.
In addition to the shares previously reported on his Schedule 13D filed June 3,
1998, Mr. Stone purchased an aggregate of 77,800 shares of Common Stock in
open-market purchases made during the period commencing July 14, 1998 and ended
December 29, 1999. The purchase price of the shares of Common Stock ranged
between $3.25 per share and $1.0625 per share and all purchases by Mr. Stone
were paid out of his personal funds.
Item 4. Purpose of Transaction.
Such acquisitions of securities were made for investment purposes. Although he
has no current intention to do so, depending on market conditions and other
factors, Mr. Stone may acquire additional shares, or sell all or a portion of
his shares of Common Stock. Mr. Stone
<PAGE>
has no current plans or proposals which relate to or would result in any of the
actions set forth in subparagraphs (a) through (j) of Item 4.
Item 5. Interest in Securities of the Issuer.
See Items 7 through 11 on the cover page. During the period commencing July 14,
1998 and ended December 29, 1999, Mr. Stone purchased an aggregate of 77,800
shares of Common Stock in open-market purchases with personal funds.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
None.
Item 7. Materials to be Filed as Exhibits.
None.
<PAGE>
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: January 14, 2000 /s/ Richard Stone
-----------------------------------
Richard Stone
(120496DTI)
